Ralimetinib ( LY2228820) - CAS 862505-00-8
Ralimetinib, also known as LY2228820, is a potent and selective, ATP-competitive inhibitor of the α- and β-isoforms of p38 MAPK in vitro (IC(50) = 5.3 and 3.2 nmol/L, respectively). In cell-based assays, LY2228820 potently and selectively inhibited phosphorylation of MK2 (Thr334) in anisomycin-stimulated HeLa cells (at 9.8 nmol/L by Western blot analysis) and anisomycin-induced mouse RAW264.7 macrophages (IC(50) = 35.3 nmol/L) with no changes in phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc ≤ 10 μmol/L.
Catalog Number: I008970
CAS Number: 862505-00-8
PubChem Substance ID:355200081
Molecular Formula: C24H29FN6
Molecular Weight:420.536
Purity: ≥95%
* For research use only. Not for human or veterinary use.
Synonym
Synonyms | ;5-(2-(tert-butyl)-5-(4-fluorophenyl)-1H-imidazol-4-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine |
---|
Property
Molecular Formula: | C24H29FN6 |
---|---|
Molecular Weight | 420.536 |
Target: | p38 MAPK inhibitor |
Solubility | Soluble in DMSO, not in water |
Purity | ≥95% |
Storage | 0 - 4 °C for short term, or -20 °C for long term |
IC50 | 5.3nmol/L |
Computed Descriptor
IUPAC Name | 5-[2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine |
---|---|
InChI | InChI=1S/C24H29FN6/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30) |
InChIKey | XPPBBJCBDOEXDN-UHFFFAOYSA-N |
SMILES | CC(C)(C)CN1C2=C(C=CC(=N2)C3=C(N=C(N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N |